Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
NCT01802645
Interventional
Phase 2
Unknown status
CELIM2
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and
Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.
Mar 31,2013
All
18 Years
N/A
18 Years
N/A
91